Ligand Pharmaceuticals: Behind the $248 Million Institutional Bet on Biotech Royalty Model
Ligand Pharmaceuticals (LGND), biyofarmasötik şirketlerin late-stage klinik geliştirme programlarını finanse etmek ve desteklemek için royalty modelle
Ligand Pharmaceuticals (LGND) has entered the market as a leading platform for royalty models that finance and support late-stage clinical development programs for biopharmaceutical companies. With 34% and 60% revenue growth in recent quarters, the company is expected to deliver 8% sales and 14% EPS growth in 2026. Institutional investors are driving LGND toward its 326.63 buy point, supported by a 1.7 up/down volume ratio and $248 million in acquisitions. Captain Rıza Deniz: This move reflects the growing popularity of royalty models in the biopharmaceutical sector. LGND's success could prompt other biotech firms to reassess their royalty strategies.
Related News & Analysis
View All →
Wall Street's Riskiest Trades Surge as ARKK Leads Tech Sector Rally
‘The End of Oak Street’ Opens with $20 Million as ‘Spider-Man’ Dominates Box Office
NYT Pips Puzzle: Domino Matching Strategies and Market Expectations
AEW Collision Results: Continental Cup's Puzzling Outcomes and Market Speculations
Bank Leumi Teams Up with Galaxy Digital to Launch Crypto Trading in 2027
US Puzzle: How Markets Will React to America's Financial Uncertainty?
Latest Market News
All News →Wall Street's Riskiest Trades Surge as ARKK Leads Tech Sector Rally
‘The End of Oak Street’ Opens with $20 Million as ‘Spider-Man’ Dominates Box Office
NIH Proposes Radical Shift in Grant Review Transparency: A Threat to Scientific Meritocracy?
NYT Pips Puzzle: Domino Matching Strategies and Market Expectations
AEW Collision Results: Continental Cup's Puzzling Outcomes and Market Speculations